English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: -2.07%
Price change 2019 → 2020: 137.53%
Price change 2020 → 2021: -57.13%
Price change 2021 → 2022: -11.36%
Price change 2022 → 2023: 15.87%
Price change 2023 → 2024: -39.43%
Price change 2024 → 2025: 19.29%
Price change 2025 → 2026: 2.50%
Price change 2026 (year to date): 3.00%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.12
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -3.18
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 21.63% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="KURA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Kura Oncology, Inc. | – | 0.12 | – | 🔒 |
| DocMorris AG | – | 0.71 | +5.7 % | – |
| Pharming Group N.V. | 38.2 | 0.42 | +50.1 % | – |
| Vetoquinol S.A. | 16.2 | 0.03 | +4.2 % | – |
| BioGaia AB (publ) | 31.2 | 0.01 | +13.3 % | ★ 4/5 |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Kura Oncology, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2024 | 53.9 m | -174 m | -322.9 % | n/a |
| 2025 | 67.5 m | -279 m | -412.9 % | +25.2 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Kura Oncology, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 518 m | 438 m | 424 m | 727 m | 667 m |
| Total Debt | 6.9 m | 14.0 m | 17.2 m | 16.6 m | 20.5 m |
| Net Debt | -83.8 m | -37.8 m | -20.1 m | -208 m | -129 m |
| Equity | 507 m | 420 m | 397 m | 414 m | 174 m |
| Total assets | 534 m | 456 m | 449 m | 760 m | 738 m |
| Operating cash flow | -105 m | -110 m | -125 m | 134 m | -64.1 m |
| Investments (capex) | 1.1 m | 626,000 | 168,000 | 472,000 | 6.6 m |
| Free cash-flow | -106 m | -111 m | -125 m | 134 m | -70.7 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Kura Oncology, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Analysts' average target 24.00 USD, DCF value 17.20 USD, share price 10.26 USD.
Average target over the last 3 months: 24.00 USD (4 targets).
Track record against expectations: reported EPS above consensus 7 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Dividends and earnings
Kura Oncology, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
Next release: 10/11/2026. Expected EPS: -0.83.
Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Kura Oncology, Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| State Street | 10.7 m | 117 m | 0.0 % | +136.2 % | 2026Q2 |
| BlackRock | 10.5 m | 115 m | 0.0 % | +9.0 % | 2026Q2 |
| Vanguard Group | 5.5 m | 57.2 m | 0.0 % | +0.7 % | 2025Q4 |
| AQR Capital Management | 3.1 m | 34.3 m | 0.0 % | +47.2 % | 2026Q2 |
| Goldman Sachs | 2.3 m | 24.8 m | 0.0 % | +58.0 % | 2026Q2 |
| Geode Capital Management | 2.2 m | 24.5 m | 0.0 % | +9.6 % | 2026Q2 |
| Renaissance Technologies | 1.7 m | 18.3 m | 0.0 % | +5.1 % | 2026Q2 |
| Bank of America | 1.2 m | 12.7 m | 0.0 % | -5.6 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 29/09/2026 | Ford Kathleen | sale | 39,437 USD |
| 29/09/2026 | Leoni Mollie | sale | 309,567 USD |
| 29/09/2026 | Powl Brian T. | sale | 165,852 USD |
| 28/09/2026 | Bair Teresa Brophy | sale | 88,618 USD |
| 28/09/2026 | Ford Kathleen | sale | 72,494 USD |
| 28/09/2026 | Leoni Mollie | sale | 130,670 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Kura Oncology, Inc.
What is the Kura Oncology, Inc. share price?
Latest recorded price: 7.27 USD on 06/11/2026, for a market cap of 647 m USD.
What is the revenue of Kura Oncology, Inc.?
67.5 m USD for fiscal year 2025, with net income of -279 m USD (net margin -412.9 %).
When does Kura Oncology, Inc. report its next earnings?
The next release is expected on 10/11/2026. EPS expected by analysts: -0.83.
What do analysts say about Kura Oncology, Inc.?
Out of 17 analysts: 15 buy or strong buy, 2 hold, 0 sell or strong sell. Average price target: 24.00 USD, i.e. +133.9 % from the share price.
Is Kura Oncology, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US50127T1097).
How many employees does Kura Oncology, Inc. have?
192 full-time employees according to the latest published profile.
Who runs Kura Oncology, Inc.?
Troy Edward Wilson is the company's chief executive.
Which large funds own Kura Oncology, Inc.?
As of 2026Q2, among the large funds tracked: State Street, BlackRock, Vanguard Group, AQR Capital Management, Goldman Sachs.